Back to top
more

AMN Healthcare Services (AMN)

(Delayed Data from NYSE)

$17.43 USD

17.43
643,813

-0.42 (-2.35%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $17.43 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 246)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Humana (HUM) Ups '23 Medicare Advantage Membership Growth View

by Zacks Equity Research

Humana (HUM) expects 2023 net membership gains to be a minimum of 10.9% from the 2022 projection.

Zacks Equity Research

Why You Should Retain Centene (CNC) in Your Portfolio Now

by Zacks Equity Research

Divesting operations like PANTHERx, Magellan Specialty Health and others are going to enable Centene (CNC) to intensify its focus on its core Managed Care business.

Zacks Equity Research

Acadia (ACHC) JV Opens New Behavioral Health Unit in Fort Wayne

by Zacks Equity Research

The opening of the new hospital is in line with Acadia Healthcare's (ACHC) vision to bolster its reach in the U.S. behavioral healthcare market.

Zacks Equity Research

Henry Schein's (HSIC) New Tie-Up to Improve Patient Outcome

by Zacks Equity Research

Henry Schein's (HSIC) recent deal with VideaHealth is expected to aid dentists in proving greater transparency to patients, thus making better treatment recommendations and improving case acceptance.

Zacks Equity Research

Molina Healthcare (MOH) Up 11% in 6 Months: More Room to Run?

by Zacks Equity Research

Molina Healthcare (MOH) is well-poised for growth on growing premiums, membership increases in Government business and sufficient cash reserves.

Zacks Equity Research

Boston Scientific's (BSX) New Buyout to Expand its Portfolio

by Zacks Equity Research

Boston Scientific's (BSX) latest buyout is expected to boost its Endoscopy business by adding Apollo Endosurgery's product portfolio, which includes devices used during ELS procedures.

Zacks Equity Research

Here's Why You Should Hold on to Nevro (NVRO) Stock Now

by Zacks Equity Research

Investors continue to be optimistic about Nevro (NVRO), owing to its strength in the global SCS market.

Zacks Equity Research

Here's Why You Should Retain PerkinElmer (PKI) Stock Now

by Zacks Equity Research

PerkinElmer (PKI) continues to gain from solid product portfolio despite forex woes.

Zacks Equity Research

3 Reasons Growth Investors Will Love AMN Healthcare (AMN)

by Zacks Equity Research

AMN Healthcare (AMN) possesses solid growth attributes, which could help it handily outperform the market.

Zacks Equity Research

Here's Why You Should Hold OPKO Health (OPK) Stock For Now

by Zacks Equity Research

OPKO Health (OPK) is likely to gain from the potential in RAYALDEE that targets a growing market coupled with new collaborations and acquisitions.

Zacks Equity Research

Merit Medical (MMSI) Launches New Inflation Device basixALPHA

by Zacks Equity Research

Merit Medical (MMSI) launches basixALPHA inflation device in the United States for one-handed preparation and fast inflation with minimal exertion to streamline angioplasty procedures.

Zacks Equity Research

What You Need to Know From UnitedHealth's (UNH) Latest Outlook

by Zacks Equity Research

UnitedHealth (UNH) expects the top line to be within the range of $357-$360 billion in 2023.

Zacks Equity Research

AmerisourceBergen (ABC) Hits 52-Week High: What's Driving It?

by Zacks Equity Research

Investors are optimistic about AmerisourceBergen's (ABC) strength in its World Courier business.

Zacks Equity Research

Boston Scientific (BSX) Posts Positive Post-Market Study Data

by Zacks Equity Research

The latest PMCF study demonstrates that Boston Scientific's (BSX) ACURATE neo2 Aortic Valve System is expected to significantly improve patient outcomes.

Zacks Equity Research

Cigna (CI) Rises 18.9% in 6 Months: More Growth in Store?

by Zacks Equity Research

Cigna (CI) expects its long-term adjusted earnings per share to witness 10-13% average annual growth.

Zacks Equity Research

QIAGEN's (QGEN) New Monkeypox Test to Aid Faster Identification

by Zacks Equity Research

QIAGEN's (QGEN) latest multiplex test is expected to strengthen its portfolio and boost its fight against the global monkeypox outbreak.

Zacks Equity Research

Here's Why You Should Retain Stryker (SYK) Stock For Now

by Zacks Equity Research

Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio. However, pricing pressure weighs on it.

Zacks Equity Research

Alcon's (ALC) Latest Buyout to Enhance Its Product Portfolio

by Zacks Equity Research

Alcon's (ALC) ophthalmic pharmaceutical product suite is expected to be significantly boosted by adding new products following the recent acquisition.

Zacks Equity Research

Here's Why You Should Retain Cardinal Health (CAH) Stock Now

by Zacks Equity Research

Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and a diversified product portfolio. However, the cost of products continues to rise.

Zacks Equity Research

3 Reasons to Retain QIAGEN (QGEN) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about QIAGEN (QGEN) on the back of a series of product launches.

Zacks Equity Research

Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio

by Zacks Equity Research

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Zacks Equity Research

Alcon (ALC) Q3 Earnings Surpass Estimates, Sales Guidance Cut

by Zacks Equity Research

Alcon's (ALC) robust innovation pipeline is delivering solid results as evidenced by the strength in its comprehensive portfolio of PCIOLs, including PanOptix and Vivity.

Zacks Equity Research

Here's Why You Should Add McKesson (MCK) Stock Right Now

by Zacks Equity Research

McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.

Zacks Equity Research

Is AMN Healthcare Services (AMN) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how AMN Healthcare Services (AMN) and Biogen Inc. (BIIB) have performed compared to their sector so far this year.

Zacks Equity Research

PerkinElmer's (PKI) New Viral Vector Assays to Boost Workflows

by Zacks Equity Research

PerkinElmer's (PKI) latest launch is expected to help researchers expand options to measure viral titers, unlike ELISA and other wash-based systems.